ACET

Adicet Bio, Inc. develops gamma delta T cell therapies aimed at treating autoimmune diseases and cancer. The company focuses on the research and development of these cell therapies, which are designed to harness the immune system to target and eliminate diseased cells. Adicet operates in the biopharmaceutical sector, serving patients and healthcare providers in the oncology and immunology markets. Its activities include preclinical and clinical development of its therapeutic candidates.